Guideline Directed Medical Therapy in Patients with Heart Failure

Description

The TEAM-MGH study will formerly evaluate impact of the GDMT Clinic versus matched usual care patients on the proportion of GDMT administration over a 12 week period in approximately 300 total patients with HF across the spectrum of LVEF (with a minimum of 150 with HFrEF). The study will also assess impact of the GDMT Clinic on health status, functional capacity, biomarker profiles, cardiac remodeling and cardiovascular events.

Conditions

Heart Failure

Study Overview

Study Details

Study overview

The TEAM-MGH study will formerly evaluate impact of the GDMT Clinic versus matched usual care patients on the proportion of GDMT administration over a 12 week period in approximately 300 total patients with HF across the spectrum of LVEF (with a minimum of 150 with HFrEF). The study will also assess impact of the GDMT Clinic on health status, functional capacity, biomarker profiles, cardiac remodeling and cardiovascular events.

Guideline Directed Medical Therapy in Patients with Heart Failure

Guideline Directed Medical Therapy in Patients with Heart Failure

Condition
Heart Failure
Intervention / Treatment

-

Contacts and Locations

Boston

Massachusetts General Hospital, Boston, Massachusetts, United States, 02114

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Diagnosis of HF, including new onset disease
  • * Established cardiovascular follow up at MGH
  • * Receiving sub-optimal medical care defined as \<50% target doses of GDMT agents
  • * Age ≥18 years
  • * For HFpEF:
  • * Presence of structural heart disease (LAVi \>34 mL/Kg2, E/e' \>14, or LVH)
  • * Recent HF hospitalization or historical NT-proBNP \>300 pg/mL
  • * Planned referral to the Advanced HF program
  • * Decompensated HF
  • * End-stage kidney disease
  • * eGFR \<15 mL/min/1.73m2 or on renal replacement therapy
  • * Untreated severe valvular heart disease
  • * Advanced HF
  • * Inotropic support
  • * Transplant or MCS planned
  • * Enrolled in hospice or palliative care
  • * Life expectancy \<12 months due to non-CV disease
  • * Pericardial constriction
  • * Hypertrophic cardiomyopathy
  • * Unwillingness or inability to take GDMT
  • * Pregnancy or breast feeding

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Massachusetts General Hospital,

Study Record Dates

2025-06